Table 4. Clinical studies on DCBs in the treatment of large coronary artery lesions.

Authors/Studies (time)	Research design	Inclusion criteria	Rescue stenting	Follow-up	Key results
DCB: drug-coated balloon; DES: drug-eluting stent; LLL: late lumen loss; MACE: major adverse cardiac events; TLF: target lesion failure; TLR: target lesion revascularization.
Venetsanos, et al. (2018)[49]	DCB (221 lesions)	2.51–3.00 mm (151 lesions) ≥ 3.00 mm (70 lesions)	–	12 months	12-month TLR: 3%
Yu, et al. (2019)[60]	SeQuent Please (222 lesions)	> 2.8 mm	1 case (0.5%)	10 months on average	10-month MACE: 0 10-month TLR: 0
Lu, et al. (2019)[67]	SeQuent Please (92 cases)	> 2.75 mm	6 cases (6.4%)	9 months; 12 months	9-month LLL: -0.02 ± 0.49 mm 12-month MACE: 4.3% 12-month TLR: 4.3%
Liu, et al. (2019)[61]	SeQuent Please (120 cases)	> 3.0 mm	2 cases (1.6%)	12 months	12-month TLF: 3.4%
Rosenberg, et al. (2019)[63]	SeQuent Please (134 cases)	≥ 2.75	7%	9 months	9-month MACE: 6.1% 9-month TLR: 1.0%
DEBUT (2019)[70]	SeQuent Please (102 cases)/Integrity bare stent (106 cases)	2.5–4.0 mm	3 cases (2%)	9 months	9-month MACE: 1% vs. 14% (Pnon-inferiority < 0.00001)
Yu, et al. (2022)[65]	SeQuent Please (85 cases)/New-generation DES of Resolute Integrity, Xience Xpedition, SYNERGY and Firehawk (85 cases)	2.25–4.0 mm	2 cases (2.4%)	9 months; 12 months	9-month LLL: −0.19 ± 0.49 mm vs. 0.03 ± 0.64 mm (P = 0.019) 9-month restenosis rate: 8.9% vs. 9.6% (P = 0.877) 12-month MACE: 2.4% vs. 6.3% (P = 0.226)